Puma Biotechnology, Inc. (PBYI) Q3 2026 Earnings Call Prepared Remarks Transcript
Puma Biotechnology, Inc. (PBYI) Q3 2026 Earnings Call Prepared Remarks Transcript
Seeking Alpha11/6/2026Neutral
PBYI
Puma Biotechnology IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$425.87M
P/E Ratio
16.18
EPS
$0.51
Beta
1.33
52W High
$11.50
52W Low
$4.58
50-Day MA
$9.90
200-Day MA
$7.99
Dividend Yield
—
Profit Margin
10.30%
Forward P/E
3.46
PEG Ratio
0.03
About Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States and internationally. The company is headquartered in Los Angeles, California.
Fundamentals
| Revenue (TTM) | $231.87M |
| Gross Profit (TTM) | $170.61M |
| EBITDA | $35.50M |
| Operating Margin | 9.62% |
| Return on Equity | 22.00% |
| Return on Assets | 9.81% |
| Revenue/Share (TTM) | $4.55 |
| Book Value | $2.59 |
| Price-to-Book | 3.64 |
| Price-to-Sales (TTM) | 1.84 |
| EV/Revenue | 1.798 |
| EV/EBITDA | 9.21 |
| Quarterly Earnings Growth (YoY) | -35.30% |
| Quarterly Revenue Growth (YoY) | 1.10% |
| Shares Outstanding | $51.62M |
| Float | $39.76M |
| % Insiders | 15.37% |
| % Institutions | 75.82% |
Historical Volatility
HV 10-Day
94.94%
HV 20-Day
81.36%
HV 30-Day
69.63%
HV 60-Day
56.81%
HV Rank
75.8%
Volatility is currently expanding
Latest News
Puma Biotechnology Q3 Earnings Call Highlights
Puma Biotechnology NASDAQ: PBYI reported third-quarter 2026 revenue of $55.1 million and raised its full-year net income forecast, even as it lowered its outlook for royalties and narrowed its sales guidance for breast cancer drug NERLYNX.
MarketBeat11/6/2026Negative
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
PBYI raised its 2026 Nerlynx sales outlook after 3.5% first-half 2026 growth, with Q3 revenues expected to reach $54-$56 million.
Zacks Investment Research10/20/2026Neutral
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
Zacks Investment Research10/16/2026Positive
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to one new hire in Sept. 2026, as required under Nasdaq Listing Rule 5635(c)(4).
Business Wire10/5/2026Neutral
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
Zacks Investment Research9/18/2026Neutral
Puma Biotechnology: NERLYNX Funds Their Potential Next Oncology Franchise
NERLYNX gives PBYI an established revenue stream that can support alisertib's development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy balance sheet, which I believe should give them flexibility as their R&D progresses. Alisertib's biomarker strategy could identify responsive patients, but bear in mind that it's still a speculative asset in Phase 2 trials.
Seeking Alpha9/8/2026Positive
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Research8/12/2026Positive
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology tops Q2 earnings and revenue estimates, raises its 2026 guidance, and outlines upcoming alisertib study milestones as Nerlynx sales climb.
Zacks Investment Research8/7/2026Positive
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Puma Biotechnology, Inc. (PBYI) Q2 2026 Earnings Call Transcript
Seeking Alpha8/7/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PBYI and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 11/7/2026